We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bausch & Lomb and Galapagos Sign Agreement to Collaborate on Ophthalmic Disease Research
News

Bausch & Lomb and Galapagos Sign Agreement to Collaborate on Ophthalmic Disease Research

Bausch & Lomb and Galapagos Sign Agreement to Collaborate on Ophthalmic Disease Research
News

Bausch & Lomb and Galapagos Sign Agreement to Collaborate on Ophthalmic Disease Research

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bausch & Lomb and Galapagos Sign Agreement to Collaborate on Ophthalmic Disease Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bausch & Lomb and Galapagos NV have announced that they have entered into a collaborative research agreement. Bausch & Lomb will have the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases.

“The agreement provides access to a group of compounds that may have excellent development candidate potential,” said Praveen Tyle, Ph.D., Chief Scientific Officer, Bausch & Lomb. “The small molecule compounds under evaluation have very attractive in vitro and in vivo profiles. Our intent is to develop these compounds as unique therapies, tapping our research expertise in ophthalmic diseases.”

“We are pleased to partner with Bausch & Lomb, a leader in the development of treatments for eye diseases. Our collaboration with Bausch & Lomb gives us the opportunity to leverage select compounds in a therapeutic area that we would not otherwise pursue,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.

Advertisement